Creatine has spent three decades as a fixture of gym bags and protein-shake routines, prized for helping muscles store and access energy quickly. Now a UCLA research team is building a case that the same energy-boosting properties might make it useful somewhere far removed from the weight room: inside the immune system’s fight against tumors.
The new study, published in the journal iScience, builds on earlier work from the lab of Dr. Lili Yang, a professor of microbiology, immunology and molecular genetics at UCLA, which had already shown that creatine fuels killer T cells — the immune cells directly responsible for destroying cancer cells. This time, the researchers turned their attention to a different, equally essential player: dendritic cells, which act as the immune system’s scouts, capturing fragments of tumors and using them to activate and direct killer T cells toward the attack.
Working with mouse melanoma models and human cells in the lab, the team found that dendritic cells inside tumors ramp up their intake of creatine and appear to depend on it to function inside the tumor’s notoriously nutrient-starved environment. When researchers supplemented creatine, dendritic cell numbers and activation increased, tumor growth slowed significantly in the mice, and human dendritic cells in lab dishes showed enhanced activation as well.
The finding matters because of a persistent limitation in modern cancer immunotherapy: most approved treatments work by directly targeting killer T cells, yet only about 20% to 40% of patients see meaningful benefit. “Immunotherapy has shown remarkable promise, but it only works for a subset of patients,” said Yang, the study’s senior author. By strengthening the dendritic cells that recruit and train those T cells in the first place, rather than the T cells themselves, the researchers believe they may have identified a complementary lever that could extend immunotherapy’s benefits to more patients.
Because oral creatine has such a long track record of safe use among athletes, the researchers see a potentially faster path toward testing it in cancer patients compared to an entirely novel drug. The team says it now hopes to partner with physicians on prospective clinical trials to determine whether creatine supplementation — used either alongside existing immunotherapies or to strengthen dendritic cell-based cancer vaccines before they’re administered — can meaningfully improve outcomes in humans. For now, the approach remains unproven outside the lab: it has not been tested in human patients or evaluated by the FDA for this purpose, and researchers caution against reading the mouse results as a green light for self-directed use during cancer treatment.
